Intrust Bank NA Sells 1,640 Shares of Sanofi (SNY)
Intrust Bank NA decreased its position in Sanofi (NYSE:SNY) by 19.6% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 6,748 shares of the company’s stock after selling 1,640 shares during the period. Intrust Bank NA’s holdings in Sanofi were worth $336,000 at the end of the most recent quarter.
A number of other institutional investors have also recently bought and sold shares of SNY. Parallel Advisors LLC boosted its holdings in Sanofi by 42.5% in the second quarter. Parallel Advisors LLC now owns 2,934 shares of the company’s stock valued at $139,000 after acquiring an additional 875 shares during the last quarter. YorkBridge Wealth Partners LLC boosted its holdings in Sanofi by 33.7% in the second quarter. YorkBridge Wealth Partners LLC now owns 3,076 shares of the company’s stock valued at $147,000 after acquiring an additional 776 shares during the last quarter. Eagle Ridge Investment Management bought a new position in Sanofi in the second quarter valued at about $160,000. Bronfman E.L. Rothschild L.P. boosted its holdings in Sanofi by 142.8% in the second quarter. Bronfman E.L. Rothschild L.P. now owns 3,567 shares of the company’s stock valued at $171,000 after acquiring an additional 2,098 shares during the last quarter. Finally, Toronto Dominion Bank boosted its holdings in Sanofi by 4.6% in the second quarter. Toronto Dominion Bank now owns 4,054 shares of the company’s stock valued at $195,000 after acquiring an additional 180 shares during the last quarter. Institutional investors and hedge funds own 9.36% of the company’s stock.
Sanofi (SNY) opened at $44.56 on Tuesday. Sanofi has a 1-year low of $38.45 and a 1-year high of $50.65. The company has a current ratio of 1.59, a quick ratio of 1.16 and a debt-to-equity ratio of 0.26. The firm has a market capitalization of $113,467.86, a PE ratio of 14.20, a PEG ratio of 2.48 and a beta of 0.88.
Several equities analysts recently issued reports on the company. Cowen and Company reiterated a “market perform” rating and issued a $52.00 price target (up previously from $46.00) on shares of Sanofi in a report on Tuesday, August 1st. BidaskClub upgraded Sanofi from a “sell” rating to a “hold” rating in a report on Saturday, August 5th. J P Morgan Chase & Co restated a “neutral” rating on shares of Sanofi in a report on Friday, September 15th. HSBC Holdings plc upgraded Sanofi from a “reduce” rating to a “hold” rating in a report on Wednesday, August 30th. Finally, Zacks Investment Research cut Sanofi from a “hold” rating to a “strong sell” rating in a report on Friday, October 6th. Two research analysts have rated the stock with a sell rating, seven have assigned a hold rating and four have issued a buy rating to the stock. The stock currently has a consensus rating of “Hold” and an average price target of $53.50.
In other Sanofi news, major shareholder Sanofi acquired 105,820 shares of the business’s stock in a transaction dated Thursday, August 24th. The shares were acquired at an average price of $482.04 per share, for a total transaction of $51,009,472.80. The acquisition was disclosed in a legal filing with the SEC, which is available through this link. Insiders own 1.00% of the company’s stock.
Sanofi is a healthcare company, focused on patient needs and engaged in the research, development, manufacture and marketing of therapeutic solutions. The Company’s segments are Pharmaceuticals, Human Vaccines (Vaccines), and Other. The Pharmaceuticals segment comprises the commercial operations of various franchises, including Speciality Care (Rare Diseases, Multiple Sclerosis, and Oncology), Diabetes and Cardiovascular, Established Prescription Products, Consumer Healthcare and Generics, and research and development, production and marketing activities for all of the Company’s pharmaceuticals operations.
Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with Analyst Ratings Network's FREE daily email newsletter.